Impact of chemotherapy on ovarian function and quality of life of patients with gestational trophoblastic neoplasia

• Published in: Chung-hua fu chʿan kʿo tsa chih Vol. 53; no. 6; p. 377
• Main Authors: Xue, W, Yang, J J, Zhao, J, Ren, T, Feng, F Z, Wan, X R, Xiang, Y
• Format: Journal Article
• Language: Chinese
• Published: China 25.06.2018
• Subjects: Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cisplatin; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Dactinomycin - administration & dosage; Dactinomycin - adverse effects; Etoposide; Female; Floxuridine - administration & dosage; Floxuridine - adverse effects; Gestational Trophoblastic Disease - drug therapy; Gestational Trophoblastic Disease - pathology; Gestational Trophoblastic Disease - psychology; Humans; Menstrual Cycle - drug effects; Methotrexate - administration & dosage; Methotrexate - adverse effects; Ovary - drug effects; Ovary - physiology; Pregnancy; Quality of Life; Treatment Outcome; Vincristine - administration & dosage; Vincristine - adverse effects; Surveys and questionnaires; Antineoplastic combined chemotherapy protocols; Ovarian reserve; Gestational trophoblastic disease; Quality of life
• ISSN: 0529-567X
• DOI: 10.3760/cma.j.issn.0529-567x.2018.06.004

Using a questionnaire to evaluate different regimens of chemotherapy on ovarian function and quality of life of patients with gestational trophoblastic neoplasia (GTN) . At least 6 months after completion of chemotherapy, 200 patients with GTN treated in Peking Union Medical College Hospital from January 2010 to June 2017 were randomly selected to fill up the questionnaire. The questionnaire items were included the patient's menstrual cycles, sexual life, gestational issues and common health. The patients were divided into 3 groups by chemotherapy regimens: actinomycin D (Act-D) group, floxuridine+Act-D+vincristine (FAV) or floxuridine+Act-D+etoposide+vincristine (FAEV) group (FAV-FAEV group) , and etoposide+methotrexate+Act-D (EMA) /vincristine+cyclophosphamide (CO) or EMA/ etoposide+cisplatin (EP) group (EMA/CO-EMA/EP group) . Chi-square test was used with a significance level of -value less than 0.05. One hundred and seventy-three (86.5%,173/200) of the patients completed the questionnaire. Forty three poi